Nuclear Mechanisms Involved in Endocrine Resistance [PDF]
Frontiers in Oncology, 2021 Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens or indirectly by aromatase inhibitors which cause estrogen ...
Jürgen Dittmer
doaj +6 more sources
Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
Frontiers in Endocrinology, 2021 The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive breast cancer. The main strategy for the treatment of estrogen receptor-positive breast cancers is blocking the estrogen action on estrogen receptors by ...
Esmael Besufikad Belachew +2 more
doaj +3 more sources
Extracellular ATP promotes endocrine resistance in ER+ breast cancer through upregulation of PYGL [PDF]
Cell Death and DiseaseHormone receptor (HR)–positive breast cancer accounts for approximately 60% of all breast cancer cases, for which endocrine therapy represents the mainstay of treatment; however, the development of therapeutic resistance substantially limits its clinical
Yu-Qing Yu +7 more
doaj +2 more sources
Frontiers in Endocrinology, 2023 Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients.
Jie Yuan +11 more
doaj +3 more sources
The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways [PDF]
Frontiers in OncologySince its introduction in the 1970s, endocrine therapy that targets the estrogen receptor alpha (ERα) signaling pathway has had tremendous success in the clinic in estrogen receptor positive (ER+) breast cancer.
Gizem Yayli +3 more
doaj +2 more sources
Small Molecule Liver X Receptor Modulator GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer Cells [PDF]
BiomoleculesEndocrine therapy is an effective and common treatment strategy for estrogen receptor (ER)-positive breast cancers. However, the development of endocrine resistance, through genetic mutations and epigenetic alterations, in about 40% of treated patients ...
Shinjini Basu +4 more
doaj +2 more sources
SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2− breast cancer [PDF]
Cell Death and DiseaseEndocrine resistance poses a significant clinical challenge for patients with hormone receptor-positive and human epithelial growth factor receptor 2-negative (HR + HER2−) breast cancer. Dysregulation of estrogen receptor (ER) and ERBB signaling pathways
Kang Li +11 more
doaj +2 more sources
Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer [PDF]
Translational OncologyBackground: Tamoxifen is most often used as the first treatment for luminal A breast cancer; however, one-third of the patients are resistant to it. Numerous studies have shown that hypoxia contributes to drug resistance and is related to poor clinical ...
Enzhi Luo +3 more
doaj +2 more sources
Unraveling TIME: CD8+ T cell– and CXCL11-driven endocrine resistance in breast cancer [PDF]
The Journal of Clinical InvestigationA major unmet need in estrogen receptor–positive (ER+) breast cancer is understanding the mechanisms that underlie resistance to endocrine therapy. Although accumulating evidence suggests an association between the tumor immune microenvironment (TIME ...
Tim Kong, Cynthia X. Ma
doaj +2 more sources
Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Cancer Cell International, 2021 Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common ...
Jing Chen +6 more
doaj +1 more source